PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

NCT01074970 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

135

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Cisplatin
DRUG: Rucaparib
DRUG: Cisplatin

Sponsor

Hoosier Cancer Research Network

Collaborators

[object Object]